Why Is Snowflake Stock Trading Higher Friday?
Snowflake Inc (NYSE: SNOW) shares are trading higher after RBC Capital analyst Matthew Hedberg initiated coverage on the stock with an Outperform rating and a
Utz Brands Has The Potential To Transition From Regional Company To National Competitor, Says Analyst
Needham analyst Matt McGinley initiates coverage on Utz Brands Inc (NYSE: UTZ) with a Buy rating and a price target of $20, adding it to
Nvidia Enjoyed AI Hype, But Now It’s Approaching ‘Trough Of Disillusion’: Analyst
Shares of Nvidia Corp (NASDAQ: NVDA) slipped in early trading on Wednesday,
This Analyst Sees Durable Share Gains, Margin Expansion For Orthopedics-Focused Enovis
William Bliar has initiated coverage on Enovis Corp (NYSE: ENOV), a medical technology company focusing on the orthopedics market valued at approximately $25 billion, experiencing steady growth, especially in sub-categories such as extremities, which are growing rapidly due to
Why This UiPath Analyst Believes Stock Is Still Attractive After 100% Gain In 2023
Shares of UiPath Inc (NYSE: PATH) ended 2023 with gains of more than 100%.
Clinical Advancements In Kura Oncology’s Lead Program Ziftomenib Hint at Upsurge in Success Likelihood: Analyst
Mizuho initiated coverage on Kura Oncology Inc (NASDAQ: KURA), spotlighting the potential of ziftomenib as a first-in-class treatment for relapsed/refractory (r/r) NPM1-m acute myeloid leukemia (AML).
Genetic Testing Pioneer Myriad Genetics’ Evolution Draws Analyst Attention Amid New Product(s) Anticipation
Piper Sandler initiated coverage on Myriad Genetics Inc (NASDAQ: MYGN), noting that many investors know the company as one of the earliest pioneers of genetic testing.
Crunch Time For Utz: Analyst Predicts Flavorful Growth And Cost Efficiency
Mizuho Securities analyst John J.
Fusion’s Pharma’s Targeted Cancer Therapy Potential Gets This Analyst Bullish, Sees 100% Upside
RBC Capital Markets initiated coverage on Fusion Pharmaceuticals Inc (NASDAQ: FUSN), saying the radiopharmaceutical industry is a burgeoning area in therapeutics following the green light for Novartis AG's (NYSE:
Chewy Analyst Says Stock A ‘Tail-Wagging Opportunity’
Shares of Chewy Inc (NYSE: CHWY) have climbed on news of insiders buying its stock.